10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q2 2013

Filing Information

Form Type	10-Q
Accession Number	`0001144204-13-045992`
Period End Date	20130630
Filing Date	20130814
Fiscal Year	2013
Fiscal Period	Q2
XBRL Instance	bpth-20130630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 66 Income Statement 59 Cash Flow Statement 73

Balance Sheet 66 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$952.25K	USD	Point-in-time
Cash	`Cash`	$162.44K	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$534.05K	USD	Point-in-time
Cash	`Cash`	$1.93M	USD	Point-in-time
Cash	`Cash`	-	USD	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$195.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$279.18K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$42.58K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$46.41K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$771.62K	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.25M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	75.38M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	62.22M	shares	Point-in-time
Technology licenses - related party	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	62.22M	shares	Point-in-time
Technology licenses - related party	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	75.38M	shares	Point-in-time
Additional paid in capital for shares to be issued, shares of common stock	`CommonStockIssuableSharesIssuable`	2.54M	shares	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$928.23K	USD	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.01M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.49M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.57M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$3.74M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$2.34M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$165.90K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$57.00K	USD	Point-in-time
Accounts payable - related party	`AccountsPayableRelatedPartiesCurrent`	$8.58K	USD	Point-in-time
Accounts payable - related party	`AccountsPayableRelatedPartiesCurrent`	$10.02K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$137.66K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$4.89K	USD	Point-in-time
Accrued expense - related party	`AccruedLiabilitiesRelatedPartiesCurrent`	$26.00K	USD	Point-in-time
Accrued expense - related party	`AccruedLiabilitiesRelatedPartiesCurrent`	$37.05K	USD	Point-in-time
Accrued license payments - related party	`DueToRelatedPartiesCurrent`	$100.00K	USD	Point-in-time
Accrued license payments - related party	`DueToRelatedPartiesCurrent`	$50.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$329.24K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$267.86K	USD	Point-in-time
Long term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
Long term debt	`LongTermDebtNoncurrent`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$329.24K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$267.86K	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 6/30/13 and 12/31/12, respectively	`CommonStockValue`	$75.38K	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 6/30/13 and 12/31/12, respectively	`CommonStockValue`	$62.22K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$16.62M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$13.32M	USD	Point-in-time
Additional paid in capital for shares to be issued	`OtherAdditionalCapital`	$762.51K	USD	Point-in-time
Additional paid in capital for shares to be issued	`OtherAdditionalCapital`	-	USD	Point-in-time
Accumulated deficit during development stage	`DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage`	$12.13M	USD	Point-in-time
Accumulated deficit during development stage	`DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage`	$13.21M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$3.48M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$2.01M	USD	Point-in-time
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.74M	USD	Point-in-time
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$2.34M	USD	Point-in-time

Income Statement 59 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	-	USD	25 Qtrs
Revenue	`Revenues`	-	USD	2 Qtrs
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	2 Qtrs
Technology impairment charge	`OtherAssetImpairmentCharges`	$345.00K	USD	Annual
General & administrative	`GeneralAndAdministrativeExpense`	$480.35K	USD	2 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$483.48K	USD	2 Qtrs
Technology impairment charge	`OtherAssetImpairmentCharges`	-	USD	2 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$7.54M	USD	25 Qtrs
General & administrative	`GeneralAndAdministrativeExpense`	$252.17K	USD	1 Quarter
General & administrative	`GeneralAndAdministrativeExpense`	$240.54K	USD	1 Quarter
Technology impairment charge	`OtherAssetImpairmentCharges`	$690.00K	USD	25 Qtrs
Technology impairment charge	`OtherAssetImpairmentCharges`	$345.00K	USD	2 Qtrs
Total operating expense	`OperatingExpenses`	$428.65K	USD	1 Quarter
Total operating expense	`OperatingExpenses`	$1.08M	USD	2 Qtrs
Total operating expense	`OperatingExpenses`	$787.78K	USD	1 Quarter
Total operating expense	`OperatingExpenses`	$1.31M	USD	2 Qtrs
Total operating expense	`OperatingExpenses`	$13.53M	USD	25 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-1.08M	USD	2 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-13.53M	USD	25 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-428.65K	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.31M	USD	2 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-787.78K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.66K	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$742.00	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$1.53K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$78.74K	USD	25 Qtrs
Interest income	`InvestmentIncomeInterest`	$213.00	USD	1 Quarter
Other income	`OtherNonoperatingIncome`	-	USD	2 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	2 Qtrs
Other income	`OtherNonoperatingIncome`	-	USD	1 Quarter
Other income	`OtherNonoperatingIncome`	-	USD	1 Quarter
Other income	`OtherNonoperatingIncome`	$244.48K	USD	25 Qtrs
Other expense	`OtherNonoperatingExpense`	$4.52K	USD	25 Qtrs
Other expense	`OtherNonoperatingExpense`	$345.00	USD	2 Qtrs
Other expense	`OtherNonoperatingExpense`	$398.00	USD	2 Qtrs
Other expense	`OtherNonoperatingExpense`	$129.00	USD	1 Quarter
Other expense	`OtherNonoperatingExpense`	$269.00	USD	1 Quarter
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$1.31K	USD	2 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$1.40K	USD	1 Quarter
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$-56.00	USD	1 Quarter
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$318.70K	USD	25 Qtrs
Total Other Income (Expense)	`NonoperatingIncomeExpense`	$344.00	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-787.84K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-427.24K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.31M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-1.08M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-13.21M	USD	25 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	2 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	2 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.28	USD	25 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	58.63M	shares	2 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	66.61M	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	64.41M	shares	2 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	47.53M	shares	25 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	58.87M	shares	1 Quarter

Cash Flow Statement 73 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-787.84K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-427.24K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.31M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.08M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-13.21M	USD	25 Qtrs
Amortization	`AdjustmentForAmortization`	$96.61K	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$1.06M	USD	25 Qtrs
Amortization	`AdjustmentForAmortization`	$80.31K	USD	2 Qtrs
Technology impairment	`OtherAssetImpairmentCharges`	$345.00K	USD	Annual
Technology impairment	`OtherAssetImpairmentCharges`	-	USD	2 Qtrs
Technology impairment	`OtherAssetImpairmentCharges`	$690.00K	USD	25 Qtrs
Technology impairment	`OtherAssetImpairmentCharges`	$345.00K	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$18.50K	USD	2 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$318.50K	USD	25 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$708.60K	USD	1 Quarter
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$795.00K	USD	1 Quarter
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$346.20K	USD	1 Quarter
Stock options and warrants	`ShareBasedCompensation`	$29.56K	USD	2 Qtrs
Stock options and warrants	`ShareBasedCompensation`	$34.07K	USD	2 Qtrs
Stock options and warrants	`ShareBasedCompensation`	$3.04M	USD	25 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$279.18K	USD	25 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$142.48K	USD	2 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$84.18K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-1.95K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$3.84K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$46.41K	USD	25 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-73.11K	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$267.86K	USD	25 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-61.39K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-8.16M	USD	25 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.12M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.03M	USD	2 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	$884.71K	USD	25 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	$25.00K	USD	2 Qtrs
Purchase of exclusive license - related party	`PaymentsToAcquireIntangibleAssets`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-884.71K	USD	25 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-25.00K	USD	2 Qtrs
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	-	USD	2 Qtrs
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	$435.00K	USD	25 Qtrs
Proceeds from convertible notes	`ProceedsFromConvertibleDebt`	-	USD	2 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	-	USD	2 Qtrs
Cash repayment of convertible notes	`RepaymentsOfConvertibleDebt`	$15.00K	USD	25 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$264.71K	USD	2 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$2.52M	USD	2 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$10.56M	USD	25 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$264.71K	USD	2 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$10.98M	USD	25 Qtrs
Net cash from financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.52M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$-789.81K	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$1.93M	USD	25 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashPeriodIncreaseDecrease`	$1.39M	USD	2 Qtrs
Cash, beginning of period	`Cash`	$952.25K	USD	Point-in-time
Cash, beginning of period	`Cash`	$162.44K	USD	Point-in-time
Cash, beginning of period	`Cash`	$534.05K	USD	Point-in-time
Cash, beginning of period	`Cash`	$1.93M	USD	Point-in-time
Cash, beginning of period	`Cash`	-	USD	Point-in-time
Cash, end of period	`Cash`	$952.25K	USD	Point-in-time
Cash, end of period	`Cash`	$162.44K	USD	Point-in-time
Cash, end of period	`Cash`	$534.05K	USD	Point-in-time
Cash, end of period	`Cash`	$1.93M	USD	Point-in-time
Cash, end of period	`Cash`	-	USD	Point-in-time
Interest	`InterestPaid`	$445.00	USD	25 Qtrs
Interest	`InterestPaid`	-	USD	2 Qtrs
Interest	`InterestPaid`	-	USD	2 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	2 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	2 Qtrs
Income taxes	`IncomeTaxesPaid`	-	USD	25 Qtrs
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	-	USD	2 Qtrs
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	-	USD	2 Qtrs
Common stock issued upon conversion of convertible notes	`ConversionOfStockAmountConverted1`	$420.00K	USD	25 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.